Multicenter AIDS Cohort Study - Part B (Baltimore Center)

多中心艾滋病队列研究 - B 部分（巴尔的摩中心）

• 批准号: 7919646
• 负责人: Joseph B. Margolick
• 金额: $ 164.14万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-22 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7919646
• 关键词: Acquired Immunodeficiency Syndrome; Address; Adherence; Affect; Baltimore; Biological; Caucasians; Caucasoid Race; Characteristics; Chicago; Cohort Studies; Data; Disease Progression; Effectiveness; Enrollment; Ethnic Origin; Follow-Up Studies; Funding; Genetic; HIV-1; Hepatitis Viruses; Highly Active Antiretroviral Therapy; Host Defense; Host resistance; Human Herpesvirus 8; Immune response; Individual; Infection; Laboratories; Lead; Los Angeles; Measurement; Monitor; National Institute of Allergy and Infectious Disease; Natural History; Opportunistic Infections; Participant; Pathogenesis; Peripheral Blood Mononuclear Cell; Plasma; Play; Population; Preventive; Questionnaires; Race; Recruitment Activity; Request for Applications; Research; Research Design; Risk Factors; Role; Site; Specimen; T-Lymphocyte Subsets; Time; Vaccines; cohort; insight; member; pathogen; repository; response

DESCRIPTION (provided by applicant): The Study to Help the AIDS Research Effort (SHARE) was funded by NIAID and NCI in 1983 to study the natural history of infection with human immunodeficiency virus, type 1 (HIV). SHARE, along with similar sites in Chicago, Pittsburgh, and Los Angeles, forms the Multicenter AIDS Cohort Study (MACS). MACS participants, including 1447 enrolled in SHARE, have been followed semiannually since 1984 and have provided questionnaire data, physical exam data, laboratory data (including HIV serostatus and T-cell subset measurements), and a large repository of plasma, serum, cryopreserved peripheral blood mononuclear cells and other specimens. Evaluating and following the prevalent and incident cases of HIV-infection in SHARE and the MACS, has provided key insights into risk factors for infection with HIV-1, monitoring and mechanisms of progression of HIV infection once it is established, host defense against HIV, genetic factors affecting HIV pathogenesis, and use and efficacy of different therapies for HIV infection and for opportunistic pathogens. SHARE and MACS have just completed the recruitment of 1326 additional participants, including 352 in SHARE, who are younger and more non-Caucasian than the cohort previously recruited. This application requests the continuation of the followup of the SHARE cohort from 2004 to 2008. Expected survival and continuation in the study of HIV-infected cohort members through this time period is 88%. Specific Aims of the renewal include: determine the long-term effectiveness of highly active antiretroviral therapy (HAART); define determinants of individual responses to HAART including host genetic characteristics, co-infections (hepatitis viruses, HHV-8), immune responses to HIV, adherence, race/ethnicity; define mechanisms of host resistance to HIV infection and progression of the infection; and serve as a platform for independently funded pathogenesis studies and other collaborative research, including virological and immunological mechanisms of HIV-1 pathogenesis, laboratory correlates of disease progression or non-progression, and biological interactions between co-infections and HIV. These aims can be addressed only with continued followup of this extremely well-characterized cohort. SHARE and the MACS should continue to play a leading role in studies designed to lead to better treatments and preventive vaccines for HIV infection.

描述（由申请人提供）： 帮助艾滋病研究工作的研究 (SHARE) 于 1983 年由 NIAID 和 NCI 资助，旨在研究人类免疫缺陷病毒 1 型 (HIV) 感染的自然史。 SHARE 与芝加哥、匹兹堡和洛杉矶的类似站点一起组成了多中心艾滋病队列研究 (MACS)。 MACS 参与者（包括 1447 名参加 SHARE 的参与者）自 1984 年起每半年接受一次随访，并提供问卷数据、体检数据、实验室数据（包括 HIV 血清状态和 T 细胞子集测量）以及血浆、血清、冷冻保存的外周血单核细胞和其他样本的大型存储库。评估和跟踪 SHARE 和 MACS 中流行的和偶发的 HIV 感染病例，为 HIV-1 感染的危险因素、HIV 感染一旦建立的监测和进展机制、宿主对 HIV 的防御、影响 HIV 发病机制的遗传因素以及针对 HIV 感染和机会性病原体的不同疗法的使用和功效提供了重要见解。 SHARE 和 MACS 刚刚完成了 1326 名额外参与者的招募，其中 SHARE 中有 352 名参与者，他们比之前招募的群体更年轻，也更多非白人。该申请要求继续对 2004 年至 2008 年 SHARE 队列进行随访。在此期间，HIV 感染队列成员的预期存活率和继续研究率为 88%。更新的具体目标包括：确定高效抗逆转录病毒疗法（HAART）的长期有效性；定义个体对HAART反应的决定因素，包括宿主遗传特征、合并感染（肝炎病毒、HHV-8）、对HIV的免疫反应、依从性、种族/民族；确定宿主抵抗 HIV 感染和感染进展的机制；并作为独立资助的发病机制研究和其他合作研究的平台，包括 HIV-1 发病机制的病毒学和免疫学机制、疾病进展或不进展的实验室相关性以及合并感染和 HIV 之间的生物相互作用。只有对这一特征极其明确的群体进行持续跟踪，才能实现这些目标。 SHARE 和 MACS 应继续在旨在开发更好的 HIV 感染治疗方法和预防性疫苗的研究中发挥主导作用。